Synteract
, Inc., a full-service contract research organization (CRO), will unveil its new branding at this year’s Drug Information Association (DIA) annual meeting to be held from June 24-28 in Philadelphia at the Pennsylvania Convention Center. Synteract will exhibit in booth #1925. The company has revamped its brand to better showcase the full range of Phase I-IV services and expertise it offers biotechnology, medical device, and pharmaceutical companies.
While the company’s tagline – Shared Work-Shared Vision™ – has not changed, it has been enhanced by additional messaging that helps to define Synteract’s updated commercial strategy and strong partnership approach. The company has evolved and expanded its service offering, scale and reach in response to client demand. The new brand platform serves to reinforce that updated perspective on Synteract to the industry. The company used images of its own people in its marketing because they are the cornerstone of the global clinical development and industry expertise supporting clients every day.
The company’s continued growth on the East Coast in Research Triangle Park and in Europe has been a driver for the revamped brand identity, according to Synteract CEO Wendel Barr. “Our updated brand position reflects the evolution and growth Synteract has achieved through our commitment to serving the unique needs of emerging to midsize biotech and pharma. Our high rate of repeat business is a testament to our success, as is our support of 22 product approvals. It’s the commitment of our employees that has sustained our growth as well as that of our clients. Our continued dedication to great partnerships will be more clearly communicated through this revised messaging and strong visual identity that focuses on our people – they are Synteract.”
As part of its strategy, the company is hiring to augment its medical, clinical, biostatistics and regulatory expertise and has increased its sales and marketing investment as well. The refocused brand identity includes a fully revamped website and tradeshow booths, increased advertising, public relations and social media efforts. Synteract’s leaders are actively engaged in front of the medical, scientific and business communities through speaking engagements, contributed articles and interaction with industry associations and standards bodies such as CDISC, SCDM, DIA and others.
Barr added, “The new brand platform allows Synteract to more clearly address our differentiators within this competitive industry, giving current and prospective clients an overview of our customized approach and longstanding clinical development experience to facilitate their search for an outsourcing partner to match their specific needs. And as we move forward with European acquisition plans later this year, we want our culture to be clear.”
At DIA, the company will also host a reception at its booth #1925 on Monday, June 25th, 4:00 p.m.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.